Context Therapeutics Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Context is a preclinical-stage biopharmaceutical company developing cancer therapies and reported no product revenue. Its lead program, CTIM-76, is an anti-CD3 × anti-CLDN6 bispecific antibody intended to direct T cells against CLDN6-expressing cancer cells.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.53 million | $1.35 million |
| General and administrative expense | $2.13 million | $2.09 million |
| Operating loss | $6.67 million | $3.44 million |
| Net loss | $6.31 million | $3.44 million |
| Net loss per share, basic and diluted | $0.40 | $0.22 |
| Cash used in operating activities | $5.73 million | $3.82 million |
Interest income was $356,000, compared with $6,000 a year earlier, largely reflecting higher returns on cash balances. No meaningful gross margin or operating margin is reported because the company has no product revenue.
At March 31, 2023, cash and cash equivalents were $29.77 million, down from $35.50 million at year-end 2022. Total assets were $31.97 million; total liabilities were $3.23 million, consisting of current liabilities and lease obligations. The filing reports no borrowings or credit facility. Stockholders’ equity was $28.73 million and accumulated deficit was $50.40 million.
Changes and material developments
- Net loss increased 83% year over year; R&D expense rose 236%, while G&A expense increased 2%.
- CTIM-76 R&D expense increased to $2.09 million from $81,000, primarily due to manufacturing and IND-enabling work. ONA-XR expense was $2.09 million, up from $861,000, mainly from Phase 1b/2 ELONA trial and manufacturing costs.
- In March, the company discontinued ONA-XR development and shifted focus to CTIM-76. It recognized estimated ONA-XR closeout costs in Q1 and did not expect material future expenses from the program.
- The Integral Molecular license agreement was amended in March to remove a previously agreed milestone payment, revise a later milestone, and add payments tied to third-party research funding used for CTIM-76 development.
Outlook, risks and contingencies
Management expects to submit a CTIM-76 investigational new drug application to the FDA in Q1 2024. It estimates that March 31 cash will fund operations into late 2024; the financial-statement note separately states cash is sufficient for at least 12 months from issuance. These estimates depend on assumptions and may change. The company expects continuing losses and says substantial additional financing will be required; no financing is committed.
Key risks include clinical and regulatory uncertainty, development and manufacturing costs, reliance on third-party vendors, financing availability and potential dilution or restrictive financing terms. The filing also cites potential clinical-trial disruption from COVID-19 outbreaks. There were no material legal proceedings and no material changes to the risk factors described in the 2022 Form 10-K. Management reported disclosure controls effective at the reasonable-assurance level and no material changes in internal control over financial reporting.
Contractual exposure includes remaining Integral Molecular development and regulatory milestones of approximately $55 million, sales milestones up to $130 million, and tiered royalties up to 12% of net sales for applicable products. The Tyligand ONA-XR agreement also describes contingent manufacturing milestone payments; the filing does not clearly explain the effect of the ONA-XR discontinuation on those potential obligations.
Important facts for investors to verify
- Whether CTIM-76 IND-enabling work remains on schedule for the targeted Q1 2024 FDA submission.
- Whether the projected late-2024 cash runway remains achievable as development spending and financing needs evolve.
- How the ONA-XR discontinuation affects any remaining Tyligand obligations, and whether additional closeout costs arise.
- The conditions and timing of potential Integral Molecular milestone and research-funding payments.
- Potential dilution: 5.86 million warrants and 2.17 million stock options were outstanding at March 31, 2023; basic shares outstanding were 15.97 million.